Crossref
Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO
Journal of Clinical Oncology · 20.11.2026
DOI: 10.1200/jco-26-02424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 20.11.2026. Verfasst von Maxime Borgeaud und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Borgeaud, M., Mariniello, A., & Addeo, A. (2026). Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-02424
Vancouver
Borgeaud M, Mariniello A, Addeo A. Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-02424
BibTeX
@article{Borgeaud2026,
author = {Borgeaud, Maxime and Mariniello, Annapaola and Addeo, Alfredo},
title = {Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-02424}
}
EUVIMED